NAUT
ANALYST COVERAGE5 analysts
HOLD
-1.6%downside to target
Buy
360%
Hold
120%
Sell
120%
3 Buy (60%)1 Hold (20%)1 Sell (20%)
Full report →
PRICE
Prev Close
2.38
Open
2.38
Day Range2.29 – 2.57
2.29
2.57
52W Range0.62 – 4.31
0.62
4.31
52% of range
VOLUME & SIZE
Avg Volume
342.5K
FUNDAMENTALS
P/E Ratio
-5.5x
Not profitable
EPS (TTM)
Div Yield
No dividend
Beta
1.35
Market-like
TECHNICAL
RSI (14)
39
Bearish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 22
DEx-Dividend
In 90 days
Aug 19
PDividend Pay
In 96 days
Aug 25

NAUT News

About

born from the founders’ recognition that their diverse but complementary skills and experiences would enable them to successfully address challenges that others had not, the company set about solving a vexing problem: how to bring true proteomics to the world in a way that accelerates therapeutic development, dramatically improves medical diagnostics, and makes personalized and predictive medicine a reality. the extraordinary team at nautilus represents a wide spectrum of disciplines and expertise, including: protein chemists, chip designers, molecular biologists, data scientists, material scientists, biophysicists, optical engineers, microfluidics engineers, bioinformaticists, software engineers, and more. nautilus is positioned to revolutionize proteomics, transform the way drugs are developed, and significantly improve the way human health is managed.

Industry
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Parag MallickCo-Founder, Chief Scientist & Director
Subra SankarSenior Vice President of Product Development
Kentaro SuzukiChief Marketing Officer
Matthew Murphy ESQ.General Counsel
Sujal PatelCo-Founder, Chief Executive Officer, President, Secretary & Director
Amber FaustVice President of Global Sales
Anna MowryChief Financial Officer & Treasurer
Gwen E. WeldChief People Officer